Europe Could Conditionally Approve Gilead’s Remdesivir In Next Few Days
Yuan Slumps as US-Chinese Tensions Rise
What is our “variant perception” to the market?
Reopening Trump’s Trade: Gold Is On The Move
Will PMIs Show Economies Hit Bottom? Are US-China Tensions Rising Again?
5 things to know about Chinese and emerging market stocks
Sweden’s Economy: Predicting is Not Showing
Cherry Thomas joins Caribou as SVP of clinical development; Artax locks in Joseph Lobacki as CEO
Social Norms for the Era of Social Distancing
Investment Implications of COVID-19: Worse Before Better
Coronavirus Spreads to Emerging Debt
COVID-19 Implications: Updated Thinking
COVID-19: Science and Economics
Navigating the Low-Rate Environment
COVID-19 Leads to Dispersion in EM Debt
Engagement in the Work-From-Home Era
Coronavirus – weekly update – 13 May 2020
Coronavirus – weekly update – 11 May 2020
New warnings of euro crisis! What's the trade?
Mastercard Sees Steady Improvements As Spending Begins To Recover
Federal Reserve KaPow-ells Markets
Miracles Aren’t Shovel-Ready
Time To Build Without VCs
Has The Stock Market Gone Mad? Long Gambling Ideas
Covid-19 roundup: Gilead selects 5 generic manufacturing partners for remdesivir; CanSino outlines PhI/II study in Canada
Will Powell have any more Luck Pushing against Negative Rate Expectations in the US?
Gilead Signs Remdesivir Licensing Agreements With Five Drugmakers
CEO Albert Bourla On Pfizer’s Involvement With Covid-19
Emerging from the Great Lockdown in Asia and Europe
Negative interest rates are coming, investors taking action